<DOC>
	<DOC>NCT01353963</DOC>
	<brief_summary>This is a non-interventional study to review safety data on administration of desvenlafaxine succinate among Filipino patients with MDD and VMS per usual clinical practice within the first three years post commercial distribution.</brief_summary>
	<brief_title>Desvenlafaxine Succinate (Pristiq): Postmarketing Surveillance Study Among Filipino Patients</brief_title>
	<detailed_description>post marketing surveillance none</detailed_description>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder, Major</mesh_term>
	<mesh_term>Desvenlafaxine Succinate</mesh_term>
	<criteria>Patients diagnosed with major depressive disorder and vasomotor symptoms secondary to menopause prescribed with desvenlafaxine succinate Hypersensitivity to desvenlafaxine succinate</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>